Medical News

RSS

Columbia Laboratories to sell progesterone related assets and 11.2M shares to Watson Pharmaceuticals

Columbia Laboratories, Inc. has entered into a definitive agreement to sell substantially all of its progesterone related assets and 11.2 million shares of common stock to Watson Pharmaceuticals, Inc. for a $47 million upfront payment plus royalties of 10 to 20 percent of annual net sales of certain progesterone products. Additional payments up to $45.5 million can be earned by the successful completion of clinical development milestones in the ongoing PREGNANT Study, regulatory filings, receipt of regulatory approvals and product launches.

4 Mar 2010

Chay Enterprises merges with DMI Life Sciences to form Ampio Pharmaceuticals

Chay Enterprises, Inc. is pleased to announce today that the company has merged with DMI Life Sciences, Inc to form Ampio Pharmaceuticals, Inc. Ampio Pharmaceuticals will trade on the NASDAQ BB under the symbol CHYE. "We have asked FINRA to change our symbol," said Don Wingerter, Ampio Pharmaceuticals' CEO, "and expect to be trading under our new symbol in less than thirty days."

4 Mar 2010

New Jersey hospital offers luxury with health, wellness

The Philadelphia Inquirer reports on Virtua Health system's newly opened Health and Wellness Center in New Jersey, and calls it "the new face of luxury." The center was a $31 million investment by the non-profit group and it is expected to do well. "While many New Jersey hospitals grapple with barely-there operating margins and a national slowdown in construction, Virtua is growing.

4 Mar 2010

Dermatologist speaks about common forms of hair loss and treatment options at 68th Annual Meeting

For many women, unexplained hair loss can take a significant psychological toll on their overall quality of life. From altering their hairstyle to hide a thinning part to scaling back their hair care regimen in an effort to halt further hair loss, women try countless ways to cover up this problem - and the results are often lukewarm at best.

4 Mar 2010

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the University of Michigan to evaluate bone defect repairs using human stem cells. The one-year project, beginning in March, will be funded through the proceeds of a $108,746 grant from the National Institutes of Health (NIH) under the Small Business Innovative Research Program (SBIR).

4 Mar 2010

AMA enters health IT partnerships

The American Medical Association has made deals with computer retailer Dell, and Ingenix, a subsidiary of UnitedHealth Group, to "help physicians adopt and implement electronic health records", the Chicago Tribune reports.

4 Mar 2010

Leading experts to discuss latest pharmacogenomic research at European Lung Cancer Conference

Rapid advances in drug development, genetics and multidisciplinary treatment have brought the field of oncology to a critical moment, says Dr. Rafael Rosell from the Catalan Institute of Oncology in Badalona, Spain, co-chair of the second European Lung Cancer Conference (ELCC), which will be held in Geneva, Switzerland from 28 April to 1 May 2010.

4 Mar 2010

Federal court rejects California Medicaid cuts

The San Francisco Chronicle: "A federal appeals court barred California on Wednesday from lowering Medi-Cal payments to doctors and hospitals by 5 percent and from cutting in-home care workers' wages by nearly 20 percent, saying the state's budget crisis doesn't justify violating federal laws that protect the poor and disabled.

4 Mar 2010

Washington State cracks down on prescription fraud with new paper and ink

The Seattle Post Intelligencer/Everett Herald: "Patients who get written prescriptions will see changes this summer aimed at curbing fraud. Come July 1, prescriptions will be printed on tamper-resistant paper with Mission Impossible-like ink that changes color when rubbed with a finger.

4 Mar 2010

BioSante Pharmaceuticals enters into securities purchase agreements with Great Point and Deerfield Management

BioSante Pharmaceuticals, Inc. today announced that it has received commitments from two institutional investors to purchase $18 million of securities in a registered direct offering. The investors are Great Point Partners, LLC and Deerfield Management Company. BioSante expects to receive net proceeds of approximately $17.5 million after deducting placement agent fees and other offering expenses.

4 Mar 2010

Acupuncture may reduce joint pain and stiffness caused by routine breast cancer therapy

A new study, led by researchers at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center, demonstrates that acupuncture may be an effective therapy for joint pain and stiffness in breast cancer patients who are being treated with commonly used hormonal therapies. Results were published in the Journal of Clinical Oncology.

4 Mar 2010

New generation of marketing experts may be able to test products' appeal with neuromarketing

Using advanced tools to see the human brain at work, a new generation of marketing experts may be able to test a product's appeal while it is still being designed, according to a new analysis by two researchers at Duke University and Emory University.

4 Mar 2010

Democrats now see a homestretch for health overhaul plan

President Barack Obama will take to the road next week for a push in America's heartland on health care reform.

4 Mar 2010

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.

4 Mar 2010

MetroLaser introduces new portable scanning laser Doppler vibrometer

MetroLaser is pleased to introduce the VibroMet(TM) 500 SLDV, the first truly portable scanning laser Doppler vibrometer. The vibrometer enables a user to perform a complete point-by-point vibrational analysis of any surface from a distance up to 5 meters without touching it. This system can be transported, set up, and operated by one person in real-world conditions.

4 Mar 2010

Accurate, life-saving diagnostic tools needed for screening and prevention of prostate cancer, says AdMeTech

AdMeTech President and CEO Dr. Faina Shtern told the U.S. House Committee on Oversight and Government Reform that a major national commitment is needed to create accurate, life-saving diagnostic tools for prostate cancer and end what she called "the prostate cancer crisis."

4 Mar 2010

Enigma Diagnostics opens new Regional HQ office in San Diego

Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today the opening of its new Regional HQ office in San Diego, CA and the appointment of Joel Centeno as VP Regulatory & Quality.

4 Mar 2010

AB SCIEX collaborates with Mass Spectrometry Centre to improve drug discovery and development

AB SCIEX, a global leader in life science analytical technologies, today announced that it is collaborating with the University of Geneva’s Mass Spectrometry Centre to create new workflows and analytical strategies intended to significantly improve drug discovery and development.

4 Mar 2010

Chemicals that replace ozone-destroying chlorofluorocarbons may not be eco-friendly

Chemicals that helped solve a global environmental crisis in the 1990s - the hole in Earth's protective ozone layer - may be making another problem - acid rain - worse, scientists are reporting.

4 Mar 2010

Watson Pharmaceuticals to acquire U.S. rights to Columbia's bioadhesive progesterone gel products

Watson Pharmaceuticals, Inc. today announced an agreement to expand their Women's Health brand product portfolio with the acquisition of the exclusive U.S. rights to Columbia Laboratories, Inc.'s bioadhesive progesterone gel products currently marketed under the trade names CRINONE® and PROCHIEVE® for the indications of infertility and secondary amenorrhea.

4 Mar 2010

Medical News

Columbia Laboratories to sell progesterone related assets and 11.2M shares to Watson Pharmaceuticals

Chay Enterprises merges with DMI Life Sciences to form Ampio Pharmaceuticals

New Jersey hospital offers luxury with health, wellness

Dermatologist speaks about common forms of hair loss and treatment options at 68th Annual Meeting

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

AMA enters health IT partnerships

Leading experts to discuss latest pharmacogenomic research at European Lung Cancer Conference

Federal court rejects California Medicaid cuts

Washington State cracks down on prescription fraud with new paper and ink

BioSante Pharmaceuticals enters into securities purchase agreements with Great Point and Deerfield Management

Acupuncture may reduce joint pain and stiffness caused by routine breast cancer therapy

New generation of marketing experts may be able to test products' appeal with neuromarketing

Democrats now see a homestretch for health overhaul plan

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

MetroLaser introduces new portable scanning laser Doppler vibrometer

Accurate, life-saving diagnostic tools needed for screening and prevention of prostate cancer, says AdMeTech

Enigma Diagnostics opens new Regional HQ office in San Diego

AB SCIEX collaborates with Mass Spectrometry Centre to improve drug discovery and development

Chemicals that replace ozone-destroying chlorofluorocarbons may not be eco-friendly

Watson Pharmaceuticals to acquire U.S. rights to Columbia's bioadhesive progesterone gel products

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News